Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ci Mu (慈母) is an approved oral combination nutritional supplement developed by Guangdong Hongshanhu Pharmaceutical (also known as Red Coral Pharmaceutical Group). The formulation contains calcium gluconate, zinc gluconate, and lysine hydrochloride as its active ingredients. It is primarily indicated for the treatment and prevention of calcium and zinc deficiencies, particularly in pediatric populations. Clinical applications include addressing conditions such as osteoporosis, rickets, bone developmental disorders, growth retardation, and loss of appetite (anorexia). The product provides essential elemental minerals to support normal physiological functions and bone health, while lysine hydrochloride is included to promote growth and potentially enhance the absorption of minerals. It holds the Chinese drug approval number 国药准字H20059419 and is manufactured by Hubei Wushi Pharmaceutical under license.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ci Mu.